GO
Loading...

Amgen Inc

More

  • Final Glance: Biotechnology companies Wednesday, 16 Apr 2014 | 6:02 PM ET

    Amgen Inc. rose$. 54 or. 5 percent, to $115.54. Biogen Idec rose $5.99 or 2.1 percent, to $291.48. Celgene Corp. rose $2.02 or 1.4 percent, to $141.86.

  • Midday Glance: Biotechnology companies Wednesday, 16 Apr 2014 | 1:30 PM ET

    Amgen Inc. rose$. 17 or. 1 percent, to $115.17. Biogen Idec rose $5.59 or 2.0 percent, to $291.08. Celgene Corp. rose $1.52 or 1.1 percent, to $141.36.

  • Early Glance: Biotechnology companies Wednesday, 16 Apr 2014 | 10:27 AM ET

    Amgen Inc. fell$. 34 or. 3 percent, to $114.67. Biogen Idec rose $2.08 or. 7 percent, to $287.57. Celgene Corp. rose $1.35 or 1.0 percent, to $141.19.

  • NEW YORK, April 16- Predicting when the bear market in biotech stocks will hit bottom is a hazardous prospect, but one gauge that factors in the rapid profit growth estimates for many of these companies suggests several are starting to look attractive.

  • Final Glance: Biotechnology companies Monday, 14 Apr 2014 | 6:01 PM ET

    Amgen Inc. rose $1.38 or 1.2 percent, to $113.32. Biogen Idec rose $5.52 or 2.0 percent, to $279.52. Celgene Corp. rose $1.16 or. 8 percent, to $138.06.

  • Midday Glance: Biotechnology companies Monday, 14 Apr 2014 | 2:08 PM ET

    Amgen Inc. rose $2.12 or 1.9 percent, to $114.06. Biogen Idec rose $6.40 or 2.3 percent, to $280.40. Celgene Corp. rose $1.64 or 1.2 percent, to $138.54.

  • Early Glance: Biotechnology companies Monday, 14 Apr 2014 | 10:21 AM ET

    Amgen Inc. rose$. 01 or percent, to $111.95. Biogen Idec rose $3.06 or 1.1 percent, to $277.06. Celgene Corp. rose $1.60 or 1.2 percent, to $138.50.

  • Final Glance: Biotechnology companies Friday, 11 Apr 2014 | 6:02 PM ET

    Amgen Inc. fell $2.17 or 1.9 percent, to $111.94. Biogen Idec fell $13.35 or 4.6 percent, to $274.00. Celgene Corp. fell $3.08 or 2.2 percent, to $136.90.

  • Midday Glance: Biotechnology companies Thursday, 10 Apr 2014 | 1:34 PM ET

    Amgen Inc. fell $5.13 or 4.3 percent, to $114.87. Biogen Idec fell $14.41 or 4.8 percent, to $286.27. Celgene Corp. fell $6.28 or 4.3 percent, to $141.04.

  • *France first EU country to allow biosimilar substitution. PARIS, April 10- France is going out on a limb with a plan to push the use of cheap copies of biotech drugs, triggering alarm among companies in Europe's second-biggest pharmaceutical market behind Germany.

  • Early Glance: Biotechnology companies Thursday, 10 Apr 2014 | 10:24 AM ET

    Amgen Inc. fell$. 94 or. 8 percent, to $119.06. Biogen Idec fell $9.27 or 3.1 percent, to $291.41. Celgene Corp. fell $2.36 or 1.6 percent, to $144.96.

  • *France first EU country to allow biosimilar substitution. PARIS, April 10- France is going out on a limb with a plan to push the use of cheap copies of biotech drugs, triggering alarm among companies in Europe's second-biggest pharmaceutical market behind Germany.

  • Final Glance: Biotechnology companies Wednesday, 9 Apr 2014 | 6:06 PM ET

    Amgen Inc. rose $2.02 or 1.7 percent, to $120.00. Biogen Idec rose $14.76 or 5.2 percent, to $300.68. Celgene Corp. rose $9.10 or 6.6 percent, to $147.32.

  • Early Glance: Biotechnology companies Tuesday, 8 Apr 2014 | 10:43 AM ET

    Amgen Inc. rose$. 10 or. 1 percent, to $118.92. Biogen Idec fell $4.31 or 1.5 percent, to $289.88. Celgene Corp. fell $1.32 or. 9 percent, to $137.84.

  • Final Glance: Biotechnology companies Monday, 7 Apr 2014 | 6:01 PM ET

    Amgen Inc. fell$. 29 or. 2 percent, to $118.82. Biogen Idec rose $5.92 or 2.1 percent, to $294.19. Celgene Corp. rose $1.78 or 1.3 percent, to $139.16.

  • Midday Glance: Biotechnology companies Monday, 7 Apr 2014 | 1:49 PM ET

    Amgen Inc. fell$. 47 or. 4 percent, to $118.64. Biogen Idec rose $4.41 or 1.5 percent, to $292.68. Celgene Corp. rose$. 89 or. 6 percent, to $138.27.

  • April 4- Amgen Inc said its experimental drug to treat a deadly form of skin cancer did not significantly improve overall survival rates in patients enrolled in a late-stage study.

  • April 4- Amgen Inc said its experimental drug to treat a deadly form of skin cancer shrank tumors, but did not significantly improve overall survival rates in patients enrolled in a late-stage study.

  • April 3- Amgen Inc said it would end an agreement with GlaxoSmithKline Plc for the marketing of its osteoporosis drug in some regions outside the United States. Amgen said it would take over the marketing of the drug, sold under the brand name Prolia, in most areas under the agreement, including the European Union, Switzerland, Norway, Russia and Mexico, by Dec. 31.

  • April 3- Amgen Inc said it was ending an agreement with GlaxoSmithKline Plc, under which the British company marketed Amgen's postmenopausal osteoporosis drug in some regions outside the United States.

Most Popular Video

Friday, 18 Apr 2014 | 12:00 PM ET

CNBC's Stephanie Landsman discusses how the luxury rental boom isn't confined to New York City and its boroughs, but that developers are seeing new opportunities in New Jersey.

Thursday, 17 Apr 2014 | 12:00 PM ET

CNBC's Josh Lipton and Allison+Partners Head of Digital Jeremy Rosenberg discuss what Microsoft needs to do to boost Xbox One sales as PS4 sales break the 7 million mark.

Thursday, 17 Apr 2014 | 4:13 PM ET

Dissecting today's market activity and the current state of financials, with Yra Harris, Praxis Trading partner; Larry Glazer, Mayflower Advisors; CNBC contributor Carol Roth; "Fast Money" Guy Adami and CNBC's Kate Kelly.